Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Nov;24(5):607–613. doi: 10.1111/j.1365-2125.1987.tb03219.x

Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man.

H Sinzinger 1, P Fitscha 1, J Kaliman 1, K Silberbauer 1, J O'Grady 1
PMCID: PMC1386332  PMID: 3325091

Abstract

1. Epoprostenol (prostacyclin, PGI2) has been evaluated in clinical trials in peripheral vascular disease and other conditions chiefly on the basis of its platelet inhibitory properties. These therapeutic evaluations have proceeded in the absence of evidence as to the optimum infusion regimen for epoprostenol and the choice of schedules of administration has been arbitrary. We have tried to establish an optimum infusion regimen in patients with peripheral vascular disease in terms of maximal inhibition of platelet deposition on atherosclerotic lesions in vivo together with maximal inhibition of platelet aggregation ex vivo. 2. One hundred and twenty three patients with atherosclerotic peripheral vascular disease and increased platelet uptake at atherosclerotic sites were selected. Epoprostenol was administered at a fixed dose of 5 mg kg-1 min-1 for 0.5-24 h daily for 3-7 days. 3. Infusion of epoprostenol for 6 h daily for up to 5 days caused maximum decrease in platelet uptake without tachyphylaxis and without loss of the inhibitory effect of epoprostenol on platelet aggregation responses. Longer daily infusion periods were associated with progressive loss of the anti-aggregatory effect of epoprostenol without any greater decrease in platelet uptake. Shorter daily infusion periods produced smaller decreases in platelet uptake.

Full text

PDF
607

Images in this article

611Figure 3
on p.611

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blättler W., Furrer K., Schriber K., Kofmehl R., Massini C. Platelet proteins during and after prostacyclin therapy for lower limb ischaemia--suggestion of a rebound platelet activation. Vasa. 1981;10(3):261–263. [PubMed] [Google Scholar]
  2. D'Angelo V., Villa S., Mysliwiec M., Donati M. B., de Gaetano G. Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemost. 1978 Apr 30;39(2):535–536. [PubMed] [Google Scholar]
  3. FitzGerald G. A., Smith B., Pedersen A. K., Brash A. R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984 Apr 26;310(17):1065–1068. doi: 10.1056/NEJM198404263101701. [DOI] [PubMed] [Google Scholar]
  4. Lewis P. J., Dollery C. T. Clinical pharmacology and potential of prostacyclin. Br Med Bull. 1983 Jul;39(3):281–284. doi: 10.1093/oxfordjournals.bmb.a071834. [DOI] [PubMed] [Google Scholar]
  5. Moncada S., Vane J. R. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull. 1978 May;34(2):129–135. doi: 10.1093/oxfordjournals.bmb.a071482. [DOI] [PubMed] [Google Scholar]
  6. Olsson A. G., Nilsson E. The effect of intravenous prostacyclin on resting pains and healing of ischaemic ulcers in peripheral artery disease. Prostaglandins Med. 1981 Apr;6(4):329–339. doi: 10.1016/0161-4630(81)90064-1. [DOI] [PubMed] [Google Scholar]
  7. Rubin L. J., Groves B. M., Reeves J. T., Frosolono M., Handel F., Cato A. E. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982 Aug;66(2):334–338. doi: 10.1161/01.cir.66.2.334. [DOI] [PubMed] [Google Scholar]
  8. Sinzinger H., Fitscha P. Epoprostenol and platelet deposition in atherosclerosis. Lancet. 1984 Apr 21;1(8382):905–906. doi: 10.1016/s0140-6736(84)91363-1. [DOI] [PubMed] [Google Scholar]
  9. Sinzinger H., Kolbe H., Strobl-Jäger E., Höfer R. A simple and safe technique for sterile autologous platelet labelling using "Monovette" vials. Eur J Nucl Med. 1984;9(7):320–322. doi: 10.1007/BF00276462. [DOI] [PubMed] [Google Scholar]
  10. Sinzinger H., O'Grady J., Fitscha P., Kaliman J. Effect of epoprostenol on platelet deposition on synthetic artery grafts. Lancet. 1984 Nov 24;2(8413):1212–1212. doi: 10.1016/s0140-6736(84)92766-1. [DOI] [PubMed] [Google Scholar]
  11. Sinzinger H., O'Grady J., Fitscha P., Kaliman J. Extremely-low-dose aspirin (1 mg per day) renders human platelets more sensitive to antiaggregation prostaglandins. N Engl J Med. 1984 Oct 18;311(16):1052–1052. doi: 10.1056/NEJM198410183111614. [DOI] [PubMed] [Google Scholar]
  12. Sinzinger H., Silberbauer K., Horsch A. K., Gall A. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon? Prostaglandins. 1981 Jan;21(1):49–51. doi: 10.1016/0090-6980(81)90195-7. [DOI] [PubMed] [Google Scholar]
  13. Weksler B. B., Tack-Goldman K., Subramanian V. A., Gay W. A., Jr Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation. 1985 Feb;71(2):332–340. doi: 10.1161/01.cir.71.2.332. [DOI] [PubMed] [Google Scholar]
  14. Zusman R. M., Rubin R. H., Cato A. E., Cocchetto D. M., Crow J. W., Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med. 1981 Apr 16;304(16):934–939. doi: 10.1056/NEJM198104163041603. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES